Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer

Our plain-English summary of Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer, by J. Maeda, N. Ueki, T. Ohkawa, et al (Clinical and Experimental Immunology, 1994).

The study

• Authors: J. Maeda, N. Ueki, T. Ohkawa, N. Iwahashi, T. Nakano, T. Hada, K. Higashino
• Journal: Clinical and Experimental Immunology
• Published: 1994;98(2):319-22
• Cited by: 38 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

We investigated the levels of TGF-beta in malignant pleural effusions (MPE) caused by malignant mesothelioma (MESO) or primary lung cancer. TGF-beta levels in MPE caused by MESO were 283.9 +/- 219.2 pm (mean +/- s.d.) and were three to six times higher than those due to primary lung cancers (P < 0.01 or P < 0.05). We also evaluated TGF-beta 1- and beta 2-like activities in MPE using specific polyclonal antibodies. Although TGF-beta 1-like activity could be detected in all cases, TGF-beta 2-like activities were detected in five of seven in MESO and in a few cases with primary lung cancer. These results demonstrate that the levels of total TGF-beta and TGF-beta 2-like activity may be clinically useful to differentiate MESO from primary lung cancer. Our data also suggest that TGF-beta may help further characterize the clinical features of MESO.

In plain English

This laboratory study from Japan measured a growth-regulating protein, transforming growth factor-beta (TGF-beta), in fluid drained from around the lungs (pleural effusions). Samples came from 7 patients with malignant mesothelioma and from patients with primary lung cancer: 7 with small cell carcinoma, 10 with adenocarcinoma and 6 with squamous cell carcinoma. For comparison, 15 patients with tuberculous pleurisy also gave samples. The study did not examine asbestos exposure. Average total TGF-beta in the mesothelioma fluids was 283.9 pM (standard deviation 219.2). That was three to six times higher than in the lung cancer or tuberculosis fluids, a statistically significant difference. The lung cancer and tuberculosis groups did not differ significantly from one another. A form called TGF-beta2-like activity made up 30 to 50% of activity in 5 of 7 mesothelioma fluids, 1 of 10 adenocarcinoma fluids and 1 of 6 squamous cell fluids. The other samples showed only TGF-beta1-like activity. The authors concluded that these results may be clinically useful for telling mesothelioma apart from primary lung cancer, and that further studies are needed. They did not determine how much of the TGF-beta came from cancer cells.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory comparison of pleural fluid samples from patients grouped by diagnosis (cell growth-inhibition assay with antibody neutralization)
• Who was studied: Malignant pleural effusions from 7 patients with small cell lung carcinoma, 10 with adenocarcinoma, 6 with squamous cell carcinoma and 7 with malignant mesothelioma, plus benign effusions from 15 patients with tuberculous pleurisy. The authors were at Hyogo College of Medicine, Japan. Dates are not given.
• Exposure: No asbestos exposure was assessed. The study compared TGF-beta levels in pleural fluid across diagnoses.
• Main results:
  • Mean total TGF-beta (plus or minus standard deviation): small cell carcinoma 48.3 ± 22.6 pM, adenocarcinoma 89.3 ± 47.7 pM, squamous cell carcinoma 74.7 ± 49.9 pM, malignant mesothelioma 283.9 ± 219.2 pM, tuberculous pleurisy 46.1 ± 35.2 pM.
  • TGF-beta levels in mesothelioma effusions were three to six times higher than in effusions from primary lung cancer or tuberculosis (P less than 0.01 or P less than 0.05). There was no significant difference among small cell, adenocarcinoma, squamous cell and tuberculous effusions.
  • Active TGF-beta was less than 5% of total TGF-beta in every sample.
  • Platelet factor-4 was less than 20 ng/ml in each malignant effusion. The authors took this to mean that TGF-beta released from platelets by bleeding was negligible.
  • TGF-beta2-like activity was 30 to 50% of total TGF-beta activity in 5 of 7 mesothelioma cases, 1 of 10 adenocarcinoma cases and 1 of 6 squamous cell cases. Only TGF-beta1-like activity was detected in every other malignant effusion and in every tuberculous effusion.
• The authors' conclusion: The authors concluded that their results may be clinically useful for distinguishing pleural effusions caused by mesothelioma from those caused by primary lung cancer. They suggested that TGF-beta family members may be important in the clinical features and development of mesothelioma, and said further studies are required to test this hypothesis.
• Limitations the authors state:
  • The authors did not determine how much of the TGF-beta in the effusions was produced by malignant cells.
  • The antibody against TGF-beta2 may very weakly cross-react with TGF-beta3. For this reason the isoform activities were reported as percentage growth inhibition rather than as concentrations.
  • The authors did not study the latent TGF-beta binding protein in the effusions.
  • The authors stated that further laboratory and patient studies are required to test their hypothesis.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Transforming Growth Factor-beta (TGF-β), Pleural Effusion, Malignant Mesothelioma, Lung Cancer.

Related studies

• Immunohistochemical localization of transforming growth factor-beta and insulin-like growth factor-I in asbestosis in the sheep model — T.C. Lee, L.I. Gold, et al. (1997)
• Transforming growth factor-beta(1) overexpression in tumor necrosis factor-alpha receptor knockout mice induces fibroproliferative lung disease — J.Y. Liu, P.J. Sime, et al. (2001)
• Distribution of transforming growth factor-beta 1, fibronectin, and smooth muscle actin in asbestos-induced pulmonary fibrosis in rats — T.D. Perdue, A.R. Brody (1994)
• Reduced tumor necrosis factor-alpha and transforming growth factor-beta1 expression in the lungs of inbred mice that fail to develop fibroproliferative lesions consequent to asbestos exposure — D.M. Brass, G.W. Hoyle, et al. (1999)
• Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases — J. Jagirdar, T.C. Lee, et al. (1997)
• Susceptibility to asbestos-induced and transforming growth factor-beta1-induced fibroproliferative lung disease in two strains of mice — G.S. Warshamana, D.A. Pociask, et al. (2002)

Browse more research in Clinical and Experimental Immunology, or return to medical research.